Olaparib is also used in gynaecological cancers as part of a combination maintenance treatment with the VEGF inhibitor bevacizumab, in patients who show either a complete or partial response to first‐line platinum‐based chemotherapy (Glossary), or those with defined HR deficiency (HRD) defined by a deleterious or suspected deleterious BRCA1/2 mutation and/or an FDA‐approved diagnostic that estimates the presence of cancer‐associated genomic rearrangements normally associated with HRD [14]. The gene discussed is BRCA1; the disease is cancer.